Author: Shannon Palus

Running shoe paper pulled for failing to disclose author’s industry ties

87507315-105.4.coverNot so fast — a paper that showed wearing Vibram FiveFingers (resembling foot gloves) “may help reduce running-related injuries” has been removed after the editors realized the first author is on Vibram’s advisory board.

Managing editor Noelle A. Boughanmi told us there’s no retraction here — the journal is just fixing the paper to address the relationship of podiatrist Nick Campitelli with the company featured in the article.

There is still a copy of the paper on PubMed, which suggests these “minimalist shoes” strengthen key muscles.

The paper was published online by the Journal of the American Podiatric Medical Association. It was removed after editors realized that “the author did not fully disclose some involvement with the company,” Boughanmi said:

Continue reading Running shoe paper pulled for failing to disclose author’s industry ties

Trouble with data proves toxic for a pair of toxicology papers

logoA pair of papers about the risks of titanium dioxide nanoparticles that share many of the same authors has been retracted from a toxicology journal following an investigation at Soochow University in China.

Particle and Fibre Toxicology is retracting the papers for problems with the statistical methods and missing data, as well as for sharing figures.

Here’s the note for “Intragastric exposure to titanium dioxide nanoparticles induced nephrotoxicity in mice, assessed by physiological and gene expression modifications:”

Continue reading Trouble with data proves toxic for a pair of toxicology papers

Researchers, need $100? Just mention Cyagen in your paper!

Screen Shot 2015-08-14 at 1.15.29 PM

A bioscience company is offering researchers a voucher — $100 and up — to mention them in published papers.

“PCR just got a new meaning,” Cyagen Biosciences, Inc. declares on their website: “Publish”, “Cite,” “Reward.”

The company, which makes bioscience tools, is offering scientists vouchers in exchange for a nod:  Continue reading Researchers, need $100? Just mention Cyagen in your paper!

“Disagreement about the relative contributions” of authors burns capacitor paper

S02663538A 2014 paper on a component for thin electric circuits has been retracted from Composites Science and Technology due to a “disagreement” over author contributions, according to the retraction note.

The retraction note for “Preparation and dielectric properties of BaTiO3:epoxy nanocomposites for embedded capacitor application” is short and sweet. Here it is, in full:

Continue reading “Disagreement about the relative contributions” of authors burns capacitor paper

Gold nanoparticle paper crushed by “deliberate and fraudulent use of data”

8

Biotechnology Letters has retracted a paper on a new gene delivery technique due to “the deliberate and fraudulent use of data in the paper that had previously appeared in other papers of these two authors.”

The journal’s Editor in Chief Colin Ratledge told us that someone tipped him off that one of the authors, University of Kalyani microbiologist Keka Sarkar, had been self-plagiarizing:

I can say that a person who was familiar with the work of Dr Sarkar got in touch with about their concerns about her publications and, in particular, her paper published in Biotechnology Letters.  They supplied a dossier of her publications showing the obvious duplications of figures and that she had been using the same figures in different papers to illustrate the results from supposedly different experiments.

He found that, indeed, multiple figures in the Biotechnology Letters had appeared in other publications of Sarkar’s, some prior to the paper’s October 2013 publication, and one after. The details are in the whole retraction note:
Continue reading Gold nanoparticle paper crushed by “deliberate and fraudulent use of data”

Three more retractions for former record-holder Boldt, maybe more to come

m_cover

Justus Liebig University in Germany has been investigating concerns that Joachim Boldt, number two on the Retraction Watch Leaderboard and now up to 92 retractions, may have “manipulated” more data than previously believed.

Until now, the vast majority of Boldt’s retractions were thought to have involved inadequate ethics approval. However, new retraction notices for Boldt’s research suggest that there’s evidence the researcher also engaged in significant data manipulation.

The first retraction from the university investigation emerged last year. Two of three new notices cite the investigation specifically, and an informant at the university told us that there are more retractions to come.

Here are the retracted papers that are freshly on the record, starting with an August retraction for a 1991 Anesthesiology paper (cited 37 times, according to Thomson Scientific’s Web of Knowledge):

Continue reading Three more retractions for former record-holder Boldt, maybe more to come

BMC editors update retraction after investigation clears authors of faking peer reviews

bmc-logo

Editors at BioMed Central have taken the unusual step of updating a retraction notice after an investigation found the authors were not responsible for a peer review process gone awry. The paper is one of  dozens of other papers retracted in March for fake peer reviews.

That month, the paper “Clinical application of contrast enhanced ultrasound to diagnose benign prostatic hyperplasia” in Diagnostic Pathology was among the 43 papers retracted due to fake peer reviews. (Retractions for the phenomenon — more about it in our Nature feature here — are up to about 170.)

According to the update posted in July, an investigation into the paper by the Jiading Central Hospital in Shanghai, where the authors work, found that they “did not participate in influencing the peer review process.”

Here’s more from the update to the notice:

Continue reading BMC editors update retraction after investigation clears authors of faking peer reviews

Drugmaker accused of omitting side effect data from 2003 Risperdal paper

cover7607A 2003 paper may have left out potentially “significant” data on the long-term side-effects of an antipsychotic drug used in children, according to a former head of the U.S. Food and Drug Administration.

As reported by the Toronto Star, David Kessler is alleging that Janssen, the maker of Risperdal (and owned by Johnson & Johnson), omitted data about the risks of the drug: In particular, that boys who use it over a long period may be at risk of growing breasts.

There’s anecdotal evidence of the side effect. One family claimed the drug had caused their son to grow a pair of 46 DD-sized breasts in a lawsuit against Johnson & Johnson, reported the Wall Street Journal in February. They won, to the tune of $2.5 million. The suit is apparently just one of 1,200 like it.

The abstract of the paper, “Prolactin levels during long-term risperidone treatment in children and adolescents,” published in The Journal of Clinical Psychiatry, suggests that levels of a key hormone aren’t a problem in the long term:

Continue reading Drugmaker accused of omitting side effect data from 2003 Risperdal paper

“Gap in the proof” deletes math paper

BAZThe author of a paper on the properties of a vector space is retracting it from The Bulletin of the Australian Mathematical Society after a “false application” of a theorem led to a “gap in the proof.”

Here’s the abstract of “On a Weakly Uniformly Rotund Dual of a Banach Space,” in full:

Every Banach space with separable second dual can be equivalently renormed to have weakly uniformly rotund dual. Under certain embedding conditions a Banach space with weakly uniformly rotund dual is reflexive.

And the retraction note, published in the August issue of the journal:

Continue reading “Gap in the proof” deletes math paper

Paper on natural ways to fight cancer stem cells nixed for plagiarism

cover (1)Expert Opinion on Therapeutic Patents has retracted a 2015 review article about natural fighters of cancer stem cells for reproducing “content to a high degree of similarity without appropriate attribution or acknowledgement” from a handful of papers.

Although the editor and publisher pulled the paper, they did so with the cooperation of the authors, according to the retraction note: Continue reading Paper on natural ways to fight cancer stem cells nixed for plagiarism